Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01826786 · ClinicalTrials.gov registry record · Phase 1
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01826786 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 43 participants.
The verdict
NCT01826786, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG JNJ-42165279 (100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01826786
The ClinicalTrials.gov registry entry for NCT01826786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01826786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01826786 about?
NCT01826786 is a clinical study titled "The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers". The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.
What is the current status of trial NCT01826786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01826786?
The interventions under investigation include: Placebo (DRUG), JNJ-42165279 (100 mg) (DRUG).
Who is sponsoring clinical trial NCT01826786?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.